Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373

Oncology

Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer
Conditions:   Pancreatic Cancer;   Pancreatic Neoplasms;   Adenocarcinoma of the Pancreas
Interventions:   Procedure: 2 passes during EUS-guided fine needle biopsy;   Procedure: 3 passes during EUS-guided fine needle biopsy
Sponsor:   Orlando Health, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 15, 2021 / by / in
EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement
Condition:   Malignant Pleural Neoplasm
Interventions:   Drug: Lidocaine;   Drug: Liposomal Bupivacaine;   Other: Questionnaire Administration
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 15, 2021 / by / in
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: ERAS-007;   Drug: Encorafenib;   Drug: Cetuximab;   Drug: Palbociclib
Sponsor:   Erasca, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 15, 2021 / by / in
Open-Label Study to Evaluate Mirvetuximab Soravtansine in Cancers With High Folate Receptor-Alpha Expression
Conditions:   Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention:   Drug: Mirvetuximab soravtansine
Sponsors:   ImmunoGen, Inc.;   IQVIA Biotech
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 14, 2021 / by / in
Wet Heparinized Suction for Abdominal Cancer
Conditions:   Cancer of Pancreas;   Cancer of Stomach;   Cancer of Esophagus;   Cancer of Liver;   Cancer
Interventions:   Other: wet heparinzed suction;   Other: Microsieve;   Other: No heparin flush;   Other: No microsieve
Sponsor:   University Hospitals Cleveland Medical Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 14, 2021 / by / in
IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors
Conditions:   Advanced Endometrial Carcinoma;   Advanced Head and Neck Squamous Cell Carcinoma;   Advanced Malignant Solid Neoplasm;   Advanced Melanoma;   Advanced Ovarian Clear Cell Adenocarcinoma;   Chondrosarcoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Refractory Endometrial Carcinoma;   Refractory Head and Neck Squamous Cell Carcinoma;   Refractory High Grade Ovarian Serous Adenocarcinoma;   Refractory Melanoma;   Refractory Ovarian Clear Cell Adenocarcinoma;   Stage III Ovarian Cancer AJCC v8;   Stage III Uterine Corpus Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Uterine Corpus Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Uterine Corpus Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Uterine Corpus Cancer AJCC v8;   Stage IIIC1 Uterine Corpus Cancer AJCC v8;   Stage IIIC2 Uterine Corpus Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8
Interventions:   Drug: Glutaminase Inhibitor IPN60090;   Biological: Pembrolizumab
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 11, 2021 / by / in
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
Conditions:   Clinical Stage IV Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Metastatic Colon Carcinoma;   Metastatic Esophageal Carcinoma;   Metastatic Gastric Carcinoma;   Metastatic Liver Carcinoma;   Metastatic Malignant Digestive System Neoplasm;   Metastatic Malignant Small Intestinal Neoplasm;   Metastatic Malignant Thoracic Neoplasm;   Metastatic Pancreatic Carcinoma;   Metastatic Rectal Carcinoma;   Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8;   Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8;   Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8;   Stage IV Colon Cancer AJCC v8;   Stage IV Hepatocellular Carcinoma AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Stage IV Rectal Cancer AJCC v8;   Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8;   Stage IVA Colon Cancer AJCC v8;   Stage IVA Hepatocellular Carcinoma AJCC v8;   Stage IVA Rectal Cancer AJCC v8;   Stage IVB Colon Cancer AJCC v8;   Stage IVB Hepatocellular Carcinoma AJCC v8;   Stage IVB Rectal Cancer AJCC v8;   Stage IVC Colon Cancer AJCC v8;   Stage IVC Rectal Cancer AJCC v8
Interventions:   Other: Best Practice;   Procedure: Patient Monitoring;   Other: Questionnaire Administration
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 10, 2021 / by / in
An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women
Condition:   Mild Autonomous Cortisol Excess
Intervention:   Drug: Elagolix
Sponsors:   Icahn School of Medicine at Mount Sinai;   AbbVie
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 10, 2021 / by / in
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer
Condition:   Gastric Adenocarcinoma
Interventions:   Procedure: Gastrectomy;   Drug: Indocyanine Green;   Other: Iron Conjugated Polymers in Saline Suspension
Sponsor:   M.D. Anderson Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 9, 2021 / by / in
A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone
Condition:   Metastatic Cancer
Intervention:   Radiation: Preoperative Stereotactic Body Radiotherapy (SBRT)
Sponsor:   Memorial Sloan Kettering Cancer Center
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 9, 2021 / by / in